20x Sharper Scanner Detects Dementia and Parkinson’s Early

UZ Leuven has become the first hospital in the world to deploy the revolutionary NeuroExplorer PET scanner in routine clinical practice, a breakthrough that allows doctors to detect early signs of dementia, Parkinson’s disease, and ALS years before patients show any symptoms. The scanner offers a resolution up to 20 times higher than conventional PET scanners, enabling physicians to visualize brain abnormalities that were previously only detectable after death.

A World First in Brain Imaging

The NeuroExplorer, developed by United Imaging Healthcare in collaboration with Yale University and the University of California, Davis, was purchased by KU Leuven Research and Development (LRD) and installed at UZ Leuven. While more than 30 research centers worldwide use the scanner for scientific studies, UZ Leuven is the first institution to deploy it clinically on patients, according to VRT NWS.

“The difference in sharpness between the NeuroExplorer and a classic PET scanner is like a near-sighted person putting on glasses for the first time,” said Prof. Dr. Koen Van Laere, Head of Nuclear Medicine at UZ Leuven and Chair of the Department of Imaging and Pathology at KU Leuven, as reported by UZ Leuven. “We are now seeing brain abnormalities in very small brain nuclei and in the brainstem, which was not possible with any other imaging technique.”

Unprecedented Resolution Opens New Windows into the Brain

The NeuroExplorer uses mildly radioactive tracers to visualize biological and chemical processes in the brain with extraordinary detail. Its ultra-high spatial resolution and 10-fold sensitivity increase over previous state-of-the-art scanners allow doctors to examine brain regions involved in movement, memory, motivation, mood, and sleep—all in living patients.

“Until now, we could only see those details in the brain after death,” Van Laere told Belga News Agency. “Obviously, it’s important not to learn that information only then, but as early as possible in the disease.”

For conditions like ALS, the scanner can directly study both small brain nuclei and the deterioration of the spinal cord. For Parkinson’s disease and dementia, researchers can investigate and monitor early processes in affected brain nuclei and the connections between them with unprecedented precision.

Expanding Beyond Neurology

While the greatest expectations lie in neurology, the scanner is also being tested across a wide range of conditions. More than 30 national and international research projects are underway at UZ Leuven using the NeuroExplorer, including studies on brain tumors, movement disorders, pituitary tumors, head and neck cancers, and vascular inflammation.

The technology also holds promise for psychiatry. “We have very good hope that we can now also investigate a number of nuclei related to psychiatric disorders,” Van Laere said. “In schizophrenia, for example, the central station in the brain (the thalamus) is disrupted. That part is now visible and can yield important information.”

Accelerating Drug Development

Beyond diagnosis, the NeuroExplorer could dramatically accelerate the development of new treatments. Researchers can now directly track how medications reach and affect their targets in the brain, providing real-time data on drug efficacy that was previously impossible to obtain.

This capability could shorten clinical trial timelines and reduce the costs associated with developing therapies for neurological and psychiatric conditions, where treatment failure is often only discovered late in the development process.

Redefining ‘Normal’ Brain Aging

In a novel research direction, scientists are studying healthy volunteers of different ages to establish new definitions of what constitutes normal brain aging versus disease. The scanner’s ability to detect subtle changes means researchers can now differentiate between harmless age-related variations and early pathological signs—a distinction that has long challenged the medical community.

A Milestone for Belgian Medical Innovation

The deployment positions UZ Leuven and KU Leuven as global leaders in advanced brain imaging. According to the hospital, the first results from comparative clinical studies suggest additional diagnostic value, including for neurosurgical procedures where small tumors can now be treated earlier.

As reported by Yale School of Medicine, which co-developed the technology, the NeuroEXPLORER was named the SNMMI (Society of Nuclear Medicine and Molecular Imaging) Image of the Year in 2024, recognizing its transformative potential for brain research.

What’s Next

While the technology represents a quantum leap in diagnostic capability, questions remain about accessibility and cost. The scanner’s clinical utility will need to be validated through larger-scale studies, and healthcare systems will need to determine how to integrate such advanced imaging into standard care pathways.

Ethical considerations also emerge: what are the implications of knowing one has a neurodegenerative disease years before symptoms appear, especially when curative treatments may not yet exist for all conditions? These questions will become increasingly relevant as the technology becomes more widely adopted.

For now, the NeuroExplorer offers new hope for millions of patients worldwide who could benefit from earlier diagnosis and intervention—transforming what was once invisible into something that can be seen, studied, and ultimately, treated.